For citations:
Bessonova T.O., Mukhortova P.A., Teryan R.A., Bagdasarov A.D., Musina N.Z. Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):17-34. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.173

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.